- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01598168
Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia
March 24, 2016 updated by: McMaster University
Heparin is an anticoagulant (blood thinner) that is commonly used to treat patients with heart attacks and patients with blood clots in their legs or lungs (venous thrombosis).
Some patients develop an allergic reaction to heparin, a condition called heparin-induced thrombocytopenia (HIT).
HIT makes blood clot, which is the opposite of what heparin was designed to do.
These blood clots can lead to heart attacks, strokes, limb amputations, and death.
The objective of this 200 patient study is to determine if a new blood thinner called rivaroxaban (Xarelto) can be used to treat HIT.
Rivaroxaban can be taken by mouth, does not require blood testing, and had a low risk of bleeding when it was used to treat blood clots in other clinical trials.
If this study shows that rivaroxaban can be used to treat HIT, there will be two very important benefits.
For patients with HIT, the benefit will be having a safe, and easy-to-use drug to protect them from developing further life or limb-threatening blood clots.
For the Canadian health care system, the benefit will be having a drug that is much less expensive than the drugs currently used to treat HIT.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
Consecutive adult patients with an intermediate or high clinical probability for HIT (according to the clinical prediction rule called the "4T's Score) will receive rivaroxaban 15 mg bid while awaiting confirmation or exclusion of HIT by the local laboratory assay.
Patients who are confirmed to have HIT by the local laboratory assay will continue to receive rivaroxaban 15 mg bid until their platelet count ≥ 150 or until end of study (Day 30).
At the time of platelet count recovery (typically 4-7 days), they will be transitioned to a maintenance dose of rivaroxaban (20 mg od) for a maximum of 30 days.
Study Type
Interventional
Enrollment (Actual)
22
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Hamilton, Ontario, Canada, L8V 1C3
- Hamilton Health Sciences - Juravinski Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adult patients with 4T's Score greater than or equal to 4.
Exclusion Criteria:
- Require ongoing anticoagulant therapy for a mechanical heart valve.
- Severe renal insufficiency (CrCl<30 ml/min)
- Hepatic disease (including Child-Pugh B and C) associated with coagulopathy and a clinically relevant bleeding risk
- Inability to take oral medications.
- Ongoing requirement for systemic treatment with azole-antimycotics (except fluconazole) or HIV-protease inhibitors or strong CYP3A4 inducers
- Clinically significant active bleeding or lesions at increased risk for bleeding within the last 6 months
- Platelet count less than 80 and an ongoing need for antiplatelet therapy may be excluded at the discretion of the investigator
- Pregnant or a woman of child-bearing potential not using an adequate birth control method
- Hypersensitivity to rivaroxaban or to any ingredient in the formulation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Rivaroxaban
Rivaroxaban 15 mg bid until HIT excluded by local laboratory assay or platelets recovered.
If HIT positive and platelets have recovered, patients will receive rivaroxaban 20 mg od until Day 30.
|
Rivaroxaban 15 mg bid until HIT excluded by local laboratory assay or platelets recovered.
If HIT positive and platelets have recovered, patients will receive rivaroxaban 20 mg od until Day 30.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of new symptomatic venous and arterial thromboembolism in the study population.
Time Frame: 30 days
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of symptomatic venous and arterial thromboembolism and major bleeding in patients while on-treatment with rivaroxaban.
Time Frame: 30 days
|
30 days
|
Duration of time to platelet recovery in patients with Serotonin Release Assay (SRA) confirmed HIT
Time Frame: 30 days
|
30 days
|
Incidence of venous and arterial thromboembolism in patients with SRA confirmed HIT who receive rivaroxaban.
Time Frame: 30 days
|
30 days
|
Major bleeding in the entire study population and in patients with SRA confirmed HIT who receive rivaroxaban.
Time Frame: 30 days
|
30 days
|
To collect data to prospectively validate a new clinical prediction rule for HIT
Time Frame: 30 days
|
30 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Lori-Ann Linkins, MD, McMaster University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2013
Primary Completion (Actual)
July 1, 2015
Study Completion (Actual)
July 1, 2015
Study Registration Dates
First Submitted
May 11, 2012
First Submitted That Met QC Criteria
May 11, 2012
First Posted (Estimate)
May 15, 2012
Study Record Updates
Last Update Posted (Estimate)
March 25, 2016
Last Update Submitted That Met QC Criteria
March 24, 2016
Last Verified
March 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2012-02-09
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heparin-induced Thrombocytopenia
-
Central Hospital, Nancy, FranceRecruitingHeparin-induced ThrombocytopeniaFrance
-
Centre Hospitalier Universitaire de BesanconNot yet recruitingHeparin-induced Thrombocytopenia
-
University of ArizonaAmerican College of Clinical PharmacyRecruitingHeparin-induced ThrombocytopeniaUnited States
-
Veralox TherapeuticsCelerionCompletedHeparin-induced ThrombocytopeniaUnited States
-
Aspen Global IncorporatedTerminatedHeparin-induced ThrombocytopeniaUnited States, Bosnia and Herzegovina, Canada, France, Germany, Italy, Poland, Russian Federation, Serbia
-
Marshall UniversityUnknownHeparin-induced ThrombocytopeniaUnited States
-
Ottawa Hospital Research InstituteUnknownHeparin-induced Thrombocytopenia (HIT)Canada
-
Vanderbilt University Medical CenterAmerican Heart AssociationCompletedHeparin-induced ThrombocytopeniaUnited States
-
Central Hospital, Nancy, FranceCompletedHeparin-induced Thrombocytopenia
-
HealthCore-NERINational Heart, Lung, and Blood Institute (NHLBI)CompletedHeparin Induced ThrombocytopeniaUnited States
Clinical Trials on Rivaroxaban
-
Portola PharmaceuticalsCompleted
-
Korea University Anam HospitalRecruitingAtrial Fibrillation | Anticoagulant Adverse ReactionKorea, Republic of
-
Doasense GmbHActive, not recruitingAnticoagulant TherapyGermany
-
China National Center for Cardiovascular DiseasesNot yet recruitingStroke | Atrial Fibrillation | Major Adverse Cardiac Events | Anticoagulant Adverse Reaction
-
BayerCompleted
-
The Affiliated Hospital of Qingdao UniversityCompletedHealthy SubjectsChina
-
BayerJanssen R&D, L.L.C.Completed
-
BayerJanssen Research & Development, LLCCompletedCoronary Artery Disease | Cardiovascular DiseaseBelgium, Netherlands
-
University Hospital, GrenobleCompleted
-
Addpharma Inc.CompletedEmbolism and ThrombosisKorea, Republic of